MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression

MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis

(2011) Catherine Thériault et al.   GYNECOLOGIC ONCOLOGY

MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells

(2011) I Lakshmanan et al.   ONCOGENE

MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells

(2010) Jennifer AA Gubbels et al.   Molecular Cancer

Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes

(2010) Jennifer A. Belisle et al.   Molecular Cancer

Mitochondrial targeting of tBid/Bax: a role for the TOM complex?

(2009) M Ott et al.   CELL DEATH AND DIFFERENTIATION

CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis

(2009) Marianne Boivin et al.   GYNECOLOGIC ONCOLOGY

Cellular FLICE-inhibitory protein (c-FLIP) signalling: A key regulator of receptor-mediated apoptosis in physiologic context and in cancer

(2009) Marina Bagnoli et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Association of Cell Surface Mucins with Galectin-3 Contributes to the Ocular Surface Epithelial Barrier

(2009) Pablo Argüeso et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

MUC1 Oncoprotein Blocks Death Receptor-Mediated Apoptosis by Inhibiting Recruitment of Caspase-8

(2008) N. Agata et al.   CANCER RESEARCH

A Binding Domain on Mesothelin for CA125/MUC16

(2008) Osamu Kaneko et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)

(2008) Avi Ashkenazi et al.   JOURNAL OF CLINICAL ONCOLOGY